• Rating:
  • Manufacturer:
  • Model:
  • Available:
    In stock
  • Availability date:
  • Dosage form:
  • In stock:
    513 Items

In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

The mechanism of the antimicrobial action of sulfathiazole, including inhibition of the growth and reproduction of microorganisms, is associated with competitive antagonism with para-aminobenzoic acid and the suppression of dihydropteroate synthetase, which leads to a disruption in the synthesis of dihydrofolic acid and, ultimately, its active metabolite, tetrahydrofolic acid synthesis, necessary for tetrahydrofolic acid synthesis microbial cells.

Sulfathiazole silver has a wide spectrum of antibacterial action against mixed flora (gram-positive and gram-negative microorganisms), including Pseudomonas aeruginosa.

Inactivates and significantly reduces the infectivity of herpes viruses outside the cell and the herpes zoster virus.

The drug effectively protects the wound from infection, forms a protective layer on the surface of the wound, maintains adequate moisture and promotes wound healing.


Sulfathiazole silver has the lowest solubility among other silver salts of the sulfanilamide group, as well as high stability. Low solubility and high stability of silver sulfathiazole allows you to stay on the surface of the affected part of the skin and reduce absorption in the blood. Absorbed sulfathiazole is acetylated in the liver, after which it is excreted in the urine in the form of inactive metabolites and partially in unchanged form. The absorption of sulfathiazole increases after application of the drug to significant areas of the affected skin.

Indications for use

Argosulfan® is used topically to treat infections in such cases as:

  • skin burns of all degrees (including radiation)
  • pressure sores;
  • trophic ulcers of the leg.


Hypersensitivity to sulfatiazole, other sulfonamides or excipients.

Argosulfan® should not be used:

  • breastfeeding
  • premature infants and infants under two months of age due to the risk of subcutaneous jaundice (kernicterus)
  • patients with congenital deficiency of glucose-6-phosphate dehydrogenase due to the risk of hemolytic anemia.

Dosage and administration

Use for burns.

The drug is intended for topical use both in an open way and with the use of occlusive dressings. Argosulfan ® Does not cause darkening of the skin and linen.

After cleaning and surgical treatment of the wound, the cream is applied with a layer of 2-3 mm, observing the sterility conditions. All affected skin areas should be covered with cream during the entire treatment period. If for some reason a part of the wound is covered with cream, a thin layer of the drug should always be additionally applied. There is no need to apply an occlusive dressing to the wound, unless there are indications for the application of the dressing. Apply the cream until the wound is completely healed or until the surface of the wound is prepared for a skin transplant (surgery).

Treatment of pressure sores and trophic ulcers of the lower leg.

The drug is applied in a thin layer to the affected skin 2-3 times a day.

In the case of applying the drug to infected wounds, exudate may appear. In such cases, before applying the cream, it is necessary to wash the wound with a 0.1% aqueous solution of chlorhexidine, a 3% aqueous solution of boric acid or another antiseptic. For adults, dosing control is optional.

Special security measures

Cross-hypersensitivity to sulfonylurea derivatives, benzothiazine and p-aminosalicylic acid is possible. In each case, an allergological history should be carefully collected, especially with regard to sulfonamides. Avoid contact of the drug with eyes and mucous membranes. In case of accidental contact, rinse with plenty of water. It is also possible the development of undesirable and systemic side effects characteristic of sulfonamides.

Use the drug with caution in patients who are in a state of shock after extensive burns, and in patients after burns that are difficult to contact. Cumulation of the drug and the occurrence of adverse reactions in patients with impaired liver and kidney function is possible. Against the background of prolonged use on large areas of the skin, the level of sulfatiazole in the blood serum should be controlled, especially with diseases of the kidneys and liver, as well as the level of leukocytes, since agranulocytosis or anemia may develop.

Do not use other local medicines.

Long-term use should be avoided.

Argosulfan® contains excipients, including cetostearyl alcohol, propyl parahydroxybenzoate and methyl paraben. Due to the content of cetostearyl alcohol, the drug may cause a local skin reaction (e.g. contact dermatitis). Due to the content of propyl parahydroxybenzoate and methyl paraben, the drug may cause allergic reactions (possible late-type reactions).


active substance: silver sulphathiazole;

1 g of the drug contains silver sulfathiazole 20 mg

excipients: liquid paraffin, cetostearyl alcohol, white soft paraffin, sodium lauryl sulfate, glycerin, propyl parahydroxybenzoate (E 216), methyl parahydroxybenzoate

(E 218), potassium dihydrogen phosphate, sodium hydrogen phosphate dodecahydrate, water for injection.

Storage conditions

Store at a temperature not exceeding 25 ° C. Do not freeze.

Shelf life is 2 years.

Tags: Argosulfan® [Sulfathiazole Silver]